Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NouvSoma001
- Development stage
- Phase 1
- Lead developer
- NouvNeu Biotechnology
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intrathecal
01
Overview
NouvSoma001 is an exosome-based therapeutic candidate composed of human-induced neural stem cell-derived extracellular vesicles (hiNSC-EVs). Developed by **NouvNeu Biotechnology**, the drug is designed to utilize the natural signaling and regenerative properties of neural stem cells in a cell-free format. By delivering a multifaceted cargo of bioactive proteins, lipids, and microRNAs directly to the central nervous system, NouvSoma001 aims to modulate neuroinflammation and promote neuroregeneration. This approach is intended to provide the neuroprotective benefits of stem cell therapy while mitigating common risks such as tumorigenicity or host immune rejection associated with live cell transplantation. It is currently undergoing evaluation in early-stage clinical trials for neuroinflammatory and neurovascular conditions, including neuromyelitis optica spectrum disorders (NMOSD) and ischemic stroke.
- Other names
- human-induced neural stem cell-derived extracellular vesicleshiNSC-EVsExtracellular vesicles derived from human-induced neural stem cells
Beyond the preview
Go deeper on NouvSoma001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NouvSoma001.